Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4Cs Cough Syrup is an established over-the-counter oral medication manufactured by CAPS Holdings in Zimbabwe. The brand name '4Cs' is an acronym for the four primary symptoms it is designed to treat in infants and adults: coughs, colds, chills, and congestion. It is indicated for the symptomatic relief of various respiratory and flu-like conditions, including headache, sore throat, muscular aches, fever, nasal congestion, and tickly coughs. The product has been a staple in the Southern African Development Community (SADC) region for over 40 years and is widely recognized as a trusted cough remedy. Although the specific active pharmaceutical ingredients are not publicly disclosed in the provided documentation, the formulation is typical of multi-symptom cold and flu syrups containing small molecule agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4Cs Cough Syrup.